Company Overview

Update
Headquarters:
Evanston, IL
Funding:
$82.1M
Categories:
Biotechnology
Description:
Naurex is a clinical-stage company developing novel therapeutics for depression and other CNS disorders.

Detailed Description

Update

Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs), which modulate the receptor in a different way than existing NMDAR agents. The company’s drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex’s platform of novel NMDAR modulators.

Current Team (2)

Update

Investors (8)

Update

Offices/Locations (1)

Update
  • Office

    1801 Maple Avenue

    Suite 4300

    Evanston, IL 60201

    USA

Images (2)

Update
  • Fmqmlwuvjgsmzoofc0nc
  • 89c58801a5a21d0479f7d685eeb4518f